Immupharma PLC Change of Auditor
23 Dezember 2024 - 8:00AM
RNS Regulatory News
RNS Number : 0145R
Immupharma PLC
23 December 2024
23 December
2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Change of
Auditor
ImmuPharma PLC (LSE: IMM), the
specialist drug discovery and development company, announces the
appointment of Crowe LLP ("Crowe") as the Company's new auditor,
succeeding CLA Evelyn Partners Limited, with immediate
effect.
Crowe will conduct the audit of the
Company's financial statements for the financial year ending 31
December 2024 and a proposal to reappoint them as auditors of the
Company will be subject to the approval of shareholders at the 2025
Annual General Meeting.
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368 3550
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140,is a first-in class "immune tolerance
restorer" for the treatment of SLE (Systemic Lupus Erythematosus)
and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and
preclinical models suggest therapeutic activity for many other
autoimmune diseases that share the same mechanism of
action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPQKKBPOBDDABB
Immupharma (LSE:IMM)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Immupharma (LSE:IMM)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
